Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
- Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDP
- ADVANCE Clinical Program Reflects Takeda's Commitment to Continued Research on the Role of Immunoglobulin (IG) Therapy for Patients with Rare Neuroimmunological Disorders
- 有益的發現 CIDP的最長公共臨床研究支持HYQVIA作爲維持穩定疾病過程的有效長期治療選擇
- Takeda的ADVANCE臨床計劃反映出其在繼續研究免疫球蛋白（IG）治療罕見神經免疫性疾病患者的作用方面的承諾
Takeda (NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Results showed favorable long-term safety and tolerability of HYQVIA, and a low relapse rate, supporting its use as maintenance treatment for CIDP. These findings will be presented in a poster session on Sunday, June 23, 2024 at the Peripheral Nerve Society (PNS) Annual Meeting in Montreal, Canada.
Takeda（NYSE：TAK）今天宣佈了來自第三期ADVANCE-CIDP 3臨床試驗的數據，這是一項評估HYQVIA [含重組人透明質酸酶的人免疫球蛋白輸注10%]在慢性炎症性脫髓鞘性多神經病（CIDP）患者中安全性和有效性的長期延續研究。結果顯示HYQVIA的長期安全性和耐受性良好，複發率低，支持其作爲CIDP維持治療的選擇。這些發現將在2024年6月23日星期日，在加拿大蒙特利爾舉行的周圍神經學會（PNS）年會的海報展示中呈現。
譯文內容由第三人軟體翻譯。